Podcast Episodes
Back to Search
Did WuXi Make a Whoopsie? US-China R&D Relations in Limbo
WuXi AppTec was once again in the news this week, with speculation that the China-based biotech allegedly handed a U.S. client’s intellectual propert…
2 years, 3 months ago
Will the IRA’s Focus on the Pharmaceutical Industry Hurt the World’s Healthcare System Instead of Helping Patients?
The pharmaceutical industry is facing critical attention, particularly around drug pricing and development costs. Drug development cost is about 10% …
2 years, 3 months ago
Bayer’s sweeping executive cuts, Wegovy’s expanding reach
It was another busy week! Bayer reduced its executive suite from 14 to 8 as part of a major restructuring.
Meanwhile, the government announced it wil…
2 years, 3 months ago
Money talk: Salary trends and raises
This week, we're talking money! Following the release of BioSpace's 2024 Salary Report, we discuss salary trends and how they are impacting the bioph…
2 years, 3 months ago
Historic approval for MASH, CAR-Ts in the spotlight
Phew, what a week!
One of the most anticipated FDA decisions of the year dropped last week when the regulator approved Madrigal’s Rezdiffra as the fi…
2 years, 3 months ago
The unintended consequences of small molecules
Continuing on from our previous episode "The gap is where the pain is", this episode focuses on a healthy discussion regarding the IRA, particularly …
2 years, 3 months ago
The skinny on weight loss, donanemab and the State of the Union
The weight loss market is the gift that keeps on giving—at least for Novo Nordisk—as Wegovy continues to demonstrate its prowess with label expansion…
2 years, 3 months ago
The ABCs of ADCs: Why antibody-drug conjugates are so hot right now
These days you can hardly move without figuratively bumping into antibody-drug conjugates (ADCs). This week we discuss Pfizer's strategic priorities …
2 years, 4 months ago
The gap is where the pain is: Drug pricing and patient costs
When it comes to drug pricing, there have been (and are) bad actors in the industry, but the conversation usually ends there. Five KOLs from differen…
2 years, 4 months ago
Sweet succession: Gonzalez, patent thickets and his triumph over biosimilars
This week Lori, Greg and Tyler discuss AbbVie: how longtime CEO Richard Gonzalez navigated Humira's LOE, his victorious retirement announcement, and …
2 years, 4 months ago